Recent Updates
Recently added Catalysts
NTRA Positive Sentiment

Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

Wednesday, April 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Natera, Inc. announced the presentation of extensive evidence for its Prospera test at the 2026 ISHLT Annual Meeting. The test will be featured in 17 abstracts, including six oral presentations, showcasing its growing clinical utility in heart and lung transplantation. This highlights Natera's commitment to advancing precision medicine in transplantation.
Price reaction · baseline $205.42 (2026-04-21 close) · hit after-hours · clean, no other NTRA news in the window
day 0 close · peak
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Broad evidence supporting the Prospera test.
  • 17 abstracts presented at a major conference.
  • Collaboration with academic colleagues enhances credibility.
  • Expanding clinical utility in heart and lung transplantation.

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academic colleagues, Natera will highlight Prospera’s expanding clinical utility in heart and lung transplantation, spanning re

Frequently Asked Questions

What is the Prospera test?

The Prospera test is a cell-free DNA test developed by Natera for monitoring organ transplant health.

How many presentations were made about Prospera at ISHLT?

Prospera was featured in 17 abstracts at the ISHLT Annual Meeting.

What types of transplantation does Prospera support?

Prospera supports clinical utility in both heart and lung transplantation.

Who collaborated with Natera on the Prospera presentations?

Natera collaborated with academic colleagues to present the evidence for Prospera.

ShareAdd on Google
Tags: NTRA Viatris Investor Conferences Healthcare Natera Prospera heart transplantation lung transplantation ISHLT
Last updated: Apr 22, 2026

Biotech snapshot

Cash runway
$1092M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AtezolizumabPhase 3
Muscle-invasive Bladder Cancer →